Triff/Shutterstock
Invitae Corporation, a genetic information company, has expanded its neurology and cardiology test offering, adding 11 new panels for heritable diseases.
In addition, Invitae has updated 17 existing neurology panels and eight cardiology panels based on new discoveries in genetics research.
With this latest expansion of its test offerings, Invitae will be able to provide clinicians, patients, and payers with information on genetic changes that have been shown to influence a variety of neurologic and cardiovascular disorders, for the same price and with the same three-week average turnaround time.
The new panels will be available immediately to children’s hospitals, pediatricians, and medical genetics professionals for clinical diagnosis and care.
“Invitae is steadfast in its commitment to making high-quality genetic tests based on the latest clinical and scientific evidence available to patients and their family members,” said Robert Nussbaum, MD, chief medical officer of Invitae.
“The launch of our new and updated panels clearly illustrates our ongoing dedication to careful and comprehensive gene curation.”
Invitae’s latest expansion of its test offering is based on the latest research findings in genetics across various panels.
Understanding of the genetic links to cardiovascular disease is rapidly advancing. Invitae has expanded eight existing cardiology panels to reflect recent advances in the field to provide evidence-based test options for diagnosing aortopathies, arrhythmias, cardiomyopathies, and pulmonary hypertension.
Invitae has also included a new cardiomyopathy and skeletal muscle disease panel for patients who exhibit overlapping features of both heart and skeletal muscle disorders that analyzes up to 157 genes associated with neuromuscular disorders and cardiomyopathies.
“The role of genetic testing in diagnosing cardiovascular disease is rapidly expanding, now offering us insights that can help patients with a variety of conditions, such as dilated cardiomyopathy and primary arrhythmias,” said Ray Hershberger, MD, professor of cardiovascular medicine and director of the division of human genetics at The Ohio State University Wexner Medical Center.
“Importantly, genetic testing can also help us understand when cardiac problems are actually the first symptoms of a broader genetic disease. Expanding our ability to access clear and comprehensive genetic information will help us better diagnose and treat patients.”
Invitae Corporation, US, Insurance, Health, Genetics, Neurology, Cardiology, Risk management, Professional liability, Robert Nussbaum
